“`html
Widely Used Epilepsy Drug Poses Notable Pregnancy Risks, Global study finds
Despite expanding access to seizure medication worldwide, a new international study reveals that teh antiepileptic drug valproate continues to pose significant risks to pregnancy, raising concerns about public health in low- and middle-income countries.
A thorough study, conducted in collaboration with the World Health organization (WHO) and recently published in the journal eClinicalMedicine – part of The Lancet group – found a significant increase in the use of antiepileptic drugs between 2012 and 2022 across 73 nations. This expansion has provided vital treatment options for patients who previously had limited access to care. However, analysis coordinated by researchers at Aston university in Great Britain indicates that this growth hasn’t been uniformly accompanied by adequate safety protocols.
The primary concern highlighted by the study’s authors is the ongoing prescription of valproate, a commonly used antiepileptic. While listed as an essential medicine by the WHO, valproate is known to cause serious congenital malformations, including spina bifida and cleft palate, as well as cognitive, behavioral, and memory impairments in children exposed in utero.
“The WHO has been warning for several years about these effects,” a senior official stated, “and recommends avoiding the prescription of this drug to women and adolescents of childbearing age.” Many high-income countries have already prohibited or strictly regulated its use, implementing pregnancy prevention programs and increasing access to newer generation antiepileptic drugs.
Though, the situation differs dramatically in resource-constrained countries. “In many countries with limited resources, where choice options are expensive or difficult to access, the drug remains widely used,” researchers found. this disparity underscores a critical global health inequity.
the study, commissioned by the WHO, analyzed national sales data to assess prescribing patterns and determine the extent of potential risk exposure for women of childbearing age. This information is crucial for evaluating the effectiveness of preventative measures in each country. .
Experts emphasize that increased access to antiepileptic drugs is a positive progress for millions, but the continued use of valproate without sufficient safeguards remains a significant public health challenge. Researchers are advocating for the global standardization of prescribing practices and comprehensive education programs for both healthcare professionals and patients to mitigate risks to future generations.
The European Medicines Agency (EMA) recently reevaluated valproate-containing medications within the European Union. The Coordination group for Mutual Recognition and Decentralized Procedures – Human / CMDh,representing EU member states,has decided to strengthen warnings regarding valproate use in women and adolescents due to the risk of birth defects and developmental issues.
These intensified warnings aim to ensure patients are fully informed about the risks and that the drug is reserved for situations where it is absolutely necessary. Doctors in the EU are now advised not to prescribe valproate for epilepsy or bipolar disorder to pregnant women, those who may become pregnant, or adolescents, unless other treatments have proven ineffective or are not tolerated.
For patients for whom valproate remains the only viable treatment option, healthcare providers are instructed
